Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
In the past decades, the panorama of molecular diagnostics and care of non-small cell lung cancer (NSCLC) has rapidly evolved. The discovery of novel drivers for oncogene addiction has led to the development of additional therapeutic options in first as well as in subsequent lines. This, in turn, has fostered the search for robust and reliable molecular screening methods to support clinicians in prompt decision-making [1,2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Maria Lucia Reale, Rita Chiari, Marcello Tiseo, Fabiana Vitiello, Fausto Barbieri, Diego Cortinovis, Giovanni Luca Ceresoli, Giovanna Finocchiaro, Gianpiero Diego Romano, Pier Luigi Piovano, Alessandro Del Conte, Gloria Borra, Francesco Verderame, Vieri S Source Type: research
More News: Addiction | Cancer | Cancer & Oncology | Italy Health | Lung Cancer | Non-Small Cell Lung Cancer | Study